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Stveptococctrs prieumoniae is an important cause of morbi- 
dity and mortality worldwide [l]. Its main reservoir is 
the nasopharynx. From the nasopharynx, the organism 
can: (1) enter the bloodstream to cause invasive in- 
fections such as sepsis, meningitis and infections in 
remote foci such as arthritis, osteoniyelitis and cellulitis; 
(2) spread to adjacent mucosal tissues to cause mucosal 
infections such as otitis, sinusitis and pneumonia; and 
(3) be transmitted by direct contact and through 
aerosols to other individuals. Many individuals in a 
population are colonized with S. pneumoniae at any 
given time, and most children are colonized at some 
point during the first years of life [2-41. 
Resistance of piieumococci to antimicrobial agents, 
which was first reported in the mid-1960s [5,6], is 
increasing worldwide and has an enormous impact on 
clinicians, microbiologists, drug manufacturers, and 
public-health authorities [7,8-3 01. Antibiotic-resistant 
pneumococci are more often carried by infants and 
young children than by adults [ll-131. Furthermore, 
since most of the resistant strains belong to only a 
limited number of serotypes, which are also among the 
most common causes of pediatric infections [7,14-171, 
conjugate vaccines aimed at these antigens may provide 
a useful tool to reduce nasopharyngeal carriage and 
liniit the spread of resistant pneumococci. 
The goal of this communication is to describe the 
carriage of antibiotic-resistant S. pneumoniae in children 
in southern Israel and to review the current experience 
of the effect of the new conjugate pneumococcal vac- 
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cines on carriage of S. pneumorziae in general, and that 
of antibiotic-resistant S. pneumoniue in particular, from 
studies in our region. 
The Negev region in southern Israel constitutes 
60% of the land mass of the country while having less 
than 8% of the population. The area is largely desert, 
with high daytime temperatures, especially in the 
summer months, and low night-time temperatures, 
especially in the winter. There are about 20 days of rain 
annually. 
The two major population subgroups living in the 
area are Jews, largely concentrated in urban areas, and 
Bedouin Arabs, who are in transition from their tradi- 
tional nomadic ways to a semi-urban westernized 
lifestyle. While the Jewish population (over 77%) of the 
population) resembles that of the rest of Israel in socio- 
cultural and ethnic characteristics, except for the 
slightly lower overall socio-economic level, the Bedouins 
form a unique population group. They retain their 
traditions in certain aspects of their lives, including 
polygamy (up to four wives are allowed by Islamic law). 
This population has an extremely high birth rate. 
The high birth rate, low socio-economic status, over- 
crowding, bad housing conditions and poor hygienic 
conditions result in high rates of infectious diseases, 
including respiratory illness, gastroenteritis and parasitic 
infections. The morbidity and birth rate patterns 
among the Jewish population are similar to those of 
the developed nations. In contrast, the Bedouins have 
the lifestyle and morbidity and mortality patterns of 
developing populations, while modern diagnostic and 
health care delivery services are dl near at  hand. 
CARRIAGE OF S. P N W M O N l A E A N D  ANTIBIOTIC- 
RESISTANT S. PNEUMONIA€ DURING EARLY CHILDHOOD 
IN SOUTHERN ISRAEL 
We studied the carriage of S. pnrumoniac in healthy 
children during the first 2 years of life seen at maternal 
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child health centers during vaccination visits in the city 
of Beer-Sheva in southern Israel [18]. We were struck 
by the high prevalence of carriage of S. pneumoniae in 
general, and the carriage of resistant S. pneumoniae in 
particular, among these healthy children (Figure 1). 
Approximately one-quarter of the children carried S. 
pneumoniae at 2 months of age, the rate increasing 
gradually to almost two-thirds at age 24 months. More 
alarming was the carriage of resistant S. pneumoniae 
among these healthy children: 11% and 27% carried S. 
pneumoniae resistant to at least one antibiotic drug at 
ages 2 and 24 months, respectively, and 4% and 18%, 
respectively, carried S. pneumoniae resistant to 2 2  drugs. 
Several important risk factors for the carriage of 
resistant S. pneumoniae were identified. They included 
recent antibiotic use (relative risk (RR) 2.6; confidence 
interval (CI) 1.9-3.5); the presence of older siblings at 
home (RR for penicillin-resistant S. pneumoniae 4.3; CI 
1.0-18.1); and day-care attendance (RR 2.5; CI 
2.2-2.9). It became obvious that not only was the day- 
care attendance important in itself, but also that the 
carriage of S. pneurnoniae in general and resistant S. 
pneumoniae in particular was associated with the size of 
the day-care center as measured by the number of 
children in the group (Figure 2). 
The observation that factors such as the presence 
of siblings and day-care attendance pose a risk for 
carriage of S. pneumoniae implies that crowding is an 
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important factor which facilitates the spread of S. 
pneumoniae. We therefore compared the carriage among 
Jewish children initially studied [18] with the carriage 
among the Moslem Bedouin children in the region. 
This population is characterized by a high birth rate and 
overcrowding. In southern Israel, the crude birth rates 
in 1996 were 19.0/1000 and 55.9/1000 in Jews and 
Bedouins respectively. In addition, in Israel as a whole, 
only 4.3% of Jewish households had seven or more 
persons, while in the Moslem population 24.1% of 
households were overcrowded. As the birth rate of 
Negev Moslems is higher than that of the whole 
Moslem population of Israel (55.9/1000 and 37.2/1000 
respectively), there is no doubt that the overcrowding 
rate in southern Israel is also higher [19]. The naso- 
pharyngeal carriage of S. pneumoniae among Bedouins 
was found to be 61%, 75% and 73% at ages 2, 6 and 12 
months, respectively, compared with 26%, 39% and 
38%, respectively, among the Jews (unpublished data). 
This higher carriage rate correlated with a 4.5-fold 
(P<O.OOOl) higher rate of invasive infections among 
the Bedouins than in the Jews [20]. 
To better characterize the spread of antibiotic- 
resistant S. pneumoniae in the day-care setting, we first 
studied the carriage in a day-care facility located in the 
city of Beer-Sheva, where nasopharyngeal cultures from 
S. pneumoniae were obtained every 2 weeks during a 







Figure 1 Nasopharyngeal carriage of S. pneumoniae in healthy Jewish infants in Beer-Shew at ages 2-24 months (adapted 
from Dagan et al [18]). 
D a g a n  e t  a l :  I m m u n i z a t i o n  a n d  c a r r i a g e  of res is tant  p n e u m o n i a e  4S31 
70 





















Total S. pneurnoniae 
Antibiotic-resistant S. pneurnoniae 
64 
HOME (N = 0) 1 - 5  6 - 1 5  
Number of children per group 
>15 
Figure 2 Nasopharyngeal carriage of S. pneumoniae and antibiotic-resistant S. pneumoniae by day-care attendance and the 
number of children per day care group, during the second year of life in southern Israel (adapted from Dagan et al [ 181). 
ing the day-care facility, S. pneumoniue was recovered in 
362 of 573 (63%) of all cultures, and 60% of these 
isolates showed decreased susceptibility to 2 1 anti- 
biotic drugs. By molecular methods we showed an 
extensive clonal spread involving several clones. Clones 
exhibiting decreased antibiotic susceptibility were more 
frequently isolated and persisted longer than did fully 
susceptible clones. This points towards a biological 
advantage for antibiotic-resistant pneumococci in a 
‘hostile’ environment where multiple antibiotic use 
occurs frequently. 
We recently have studied children during the 
second and third year of life attendng eight day-care 
centers, each located in a different neighborhood in the 
city of Beer-Sheva, all within a 5-mile diameter [22]. 
The distribution of serotypes and antibiotic suscepti- 
bility differed significantly between day-care centers. 
Furthermore, even when the same serotype with 
identical antibiotic susceptibility patterns was found in 
various day-care centers, ribotype restriction showed 
homogeneity within day-care center, but variability 
between day-care centers. These findings emphasize 
the important role played by day-care facilities in 
the transmission and augmentation of nasopharyngeal 
carriage of resistant S. pneumoniae in the community. 
They also emphasize that it is extremely difficult to 
make any generalization on the prevalence of serotypes 
or resistance from isolated studies. 
It is established that acquisition and carriage of S. 
pneumoniae is associated with the occurrence of acute 
otitis media [23], bacteremia [24-271 and pneumonia 
[28], but is the high rate of carriage of resistant S.  
pneurnoniae associated with identical rates of disease 
caused by resistant S. pneurnoniae? It is certainly difficult 
to answer this question directly. However, much indirect 
evidence exists, at least in the case of acute otitis media. 
One way to answer this question indirectly is to examine 
the correlation between S. pnwmoniae strains isolated 
from middle ear fluid in acute otitis media and those 
isolated at the same time from the nasopharynx. We 
have recently studied 112 pairs of isolates from middle 
ear fluid and nasopharynx obtained simultaneously 
from patients with acute otitis media (unpublished 
data). The main serotypes were 6B, 9V, 14, 18C, 19F, 
19A and 23F, constituting together approximately 70% 
of all isolates. Of the 112 middle ear fluid isolates, 53% 
were penicillin susceptible and 47% were penicillin 
non-susceptible. In 90% of the cases, identical serotypes 
were isolated from both samples, and in 93‘%, identical 
susceptibility patterns were observed. 
Another way to examine the predictability of 
susceptibility of causative agents of acute otitis media 
by the patterns of nasopharyngeal isolates is to compare 
the patterns between nasopharyngeal isolates in healthy 
children and those isolated from middle ear fluid in 
children with acute otitis media. We have been study- 
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ing this issue in an ongoing research project conducted 
in Beer-Sheva. The results of our interim analysis are 
shown in Figure 3. The nasopharyngeal isolates were 
obtained from healthy children attending maternal 
children health centers for vaccination and day-care 
centers, and the middle ear fluid isolates were obtained 
from children from the same area with acute otitis 
media visiting pediatric clinics and the Pediatric Emer- 
gency Room at the Soroka University Medical Center. 
Resistance in general and penicillin resistance in parti- 
cular peaked at age 12-17 months, but was frequent 
among S. pneurnoniae isolates in all ages. A clear cor- 
relation in percentage of penicillin-resistant isolates 
and resistance to 2 1 antibiotic drugs was found in the 
nasopharyngeal isolates from healthy children and those 
from middle ear fluid from children with acute otitis 
media. The somewhat higher resistance rate among the 
middle ear fluid isolates is most probably due to the 
more frequent selection of treatment failures among the 
patients in whom tympanocentesis is performed. 
We can therefore conclude that, at least for acute 
otitis media, which is the most common reason for 
antibiotic prescription in children [29], carriage of 
resistant S. pneurnoniue in the community correlates 
with disease. This is important because of the strong 
correlation between the presence of antibiotic resistance 
among S. pneurnoniae causing acute otitis media and the 
clinical and bacteriologic outcome [29-311. Therefore, 
children nowadays find themselves in a dangerous 
vicious cycle: environmental factors associated with 
frequent and close contacts, such as the presence of 
siblings, crowding and day-care attendance, increase the 
frequency of both acute otitis media episodes and anti- 
biotic resistance. High prevalence of antibiotic resistance 
decreases the frequency of successful treatment, which 
increases the frequency of antibiotic use, which in its 
turn selects for antibiotic resistance. 
To prevent this ‘snowball’ effect, it seems reason- 
able to examine the effect of pneumococcal vaccine 
on the carriage and transmission of pneumococci in 
general, and that of antibiotic-resistant pneumococci in 
particular [7,32,33]. 
CONJUGATE PNEUMOCOCCAL VACCINES AND 
THEIR POTENTIAL EFFECT ON NASOPHARYNGEAL 
S. PNEUMONlAE IN CHILDREN 
CARRIAGE AN0 SPREAD OF ANTIBIOTIC-RESISTANT 
The new developments in conjugate pneumococcal 
vaccines are presented elsewhere in this supplement 
[34]. Table 1 summarizes the most frequent pneumo- 
coccal serotypes/serogroups associated with the various 
types of disease worldwide. Serotypes/groups 6, 9, 14, 
18, 19 and 23 are the most frequently found serotypes 
AOM ( n  = 337) 
NP - healthy subjects (n  = 1010) 
R I 1  drugs - Pen-NS 
<6 months 6-11 months 12-17months18-23 months ?24months j <6 months 6-11 months 12-17 months 1e-23 months 224 months 
Age group 
Figure 3 Proportion of isolates from nasopharynx of healthy Jewish children compared with those isolated from middle ear 
fluid in children with acute otitis media, by age group. R, resistance; Pen-NS, penicdlin non-susceptible; AOM, acute otitis 
media; NP, nasopharynx. 
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Table 1 The most common worldwide pneumococcal scrotypes/groups associated with diseases and cat-1-iage 
Serotype/group 
1 5 6 9 14 18 19 23 
Nasopharyngeal carriage + + + + + + 
Otitis media + + + + + + 
Invasive 
Developed world + + + + + + 
Developing world + + + + + + + + 
Resistant S. pnrumoniae + + + + + + 
in invasive diseases, mucosal infections and carriage 
(with the exception of types 1 and 5, which are 
frequently isolated in invasive disease in the developing 
world, but are rarely found in mucosal infection and are 
carried even more rarely even in endemic areas). 
The worldwide finding that most resistance is 
found among the serotypes most likely to cause disease 
in children [14-171 is important. It  suggests that if the 
newly developed vaccines are efficacious in reducing 
carriage of resistant S. pneumoniae, as was observed 
previously with the conjugate Haernoplzilus inzuenzae 
type b vaccines [35-391, the approach of reduction of 
spread of resistant organisms by immunization might be 
feasible, at least in part. 
The first report to show that conjugate pneumo- 
coccal vaccines might reduce the carriage of S. pnrw- 
moniae in general and that of resistant S. pneurnoniae in 
particular was published by our group in 1996 [40]. In 
this study, we examined the effect of a seven-valent 
pneumococcal conjugate vaccine (which included 
serotypes 4, 6B, SV, 14, 18C, 19F and 23F, conjugated 
to the outer-membrane protein complex of Neirreria 
meningitis group B: Pnc-OMPC) on carriage of S. 
yneumoniae and resistant S. pneumoniae of the serotypes 
included in the vaccine. 
Children aged 12-1 8 months were randomized to 
receive one dose of a conjugate heptavalent pneumo- 
coccal vaccine, two doses of the same vaccine, or one 
dose of a 23-valent native polysaccharide vaccine. Before 
immunization, pneumococcal serotypes included in 
the conjugate vaccine were isolated from 24% of the 
children, and an antibiotic-resistant pneumococcus was 
isolated from 22% of the children. The vaccines had no 
effect on carriage of non-vaccine-type pneumococci. 
In  contrast, there was a significant reduction in carriage 
of vaccine-type pneumococci 3 months after one dose 
and 1 month after a second dose of conjugate vaccine 
(from 25% to 9% and 7%, respectively; P<0.001). 
No effect was seen after vaccination with the non- 
conjugate vaccine. One year after immunization, car- 
riage of antibiotic-resistant vaccine-type pneumococci 
in children receiving conjugate vaccine was still lower 
than that in children receiving the non-conjugate 
vaccine (4% versus 1496, P=0.042) (Figure 4). 
Shortly after this report, a second report was 
published by our group. This time, the effects of 
tetravalent (serotypes 6B, 14, 19F and 23F) vaccine in 
which the polysaccharides were conjugated to diph- 
theria toxoid (Pnc-D) or tetanus toxoid (Pnc-T) were 
compared to the effect of placebo when administered 
to infants in a randomized double-blind study [41]. 
The vaccines (or placebo) were injected at 2, 4 and 6 
months of age. At 12 months of age, a native (non-con- 
jugate) polysaccharide vaccine was administered as a 
booster. 
Nasopharyngeal cultures were obtained at 2, 4, 6, 
7, 12 and 13 months of age. In general, carriage of all 
pneuniococci (vaccine- and non-vaccine-related) was 
low at age 2 months and increased with age. However, 
for the vaccine-related serotypes (6A, 6B, 14, 19F and 
23F), carriage was not increased with age in I'nc-D or 
Pnc-T recipients (Figure 5). Of  all cultures obtained 
after the full primary series, seven of 72 (lo%), three of 
62 (5%) and 19 of 70 (27%) were positive for the 
vaccine-related pneumococcal serotypes among the 
Pnc-D, Pnc-T and placebo recipients, respectively ( P  
=0.001 for Pnc-D versus placebo; P=0.014 for Pnc- 
T versus placebo). Most of the antibiotic-resistant 
isolates from the nasopharynx belonged to the vaccine- 
related serotypes. 
These studies showed clearly that conjugate pneu- 
mococcal vaccines could reduce the carriage of S. 
pneumoniae and resistant S. pneumoniae of the serotypes 
included in the vaccines. Obaro et a1 [42] raised an 
important issue regarding the effect of conjugate 
pneumococcal vaccines on carriage. The research group 
in the Gambia studied the effect of the pentavalent 
pneuniococcal vaccine (which included serotypes 6B, 
14, 18C, 19F and 23F) conjugated to C R M I C ) ~  (a non- 
toxic mutant of diphtheria toxin) on S.  pneumoniae 
carriage in infants. In the Gambia, simultaneous car- 
riage of multiple serotypes was common. Under these 
circumstances, Obaro et a1 observed two opposite 
effects of the vaccine on carriage. (1) The serotypes 
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Figure 4 Effect of 23-valent non-conjugate, one-dose seven-dent conjugate (Pnc-OMP X 1) and seven-dent two-dose 
conjugate (Pnc-OMPC X 2) vaccine on carriage of S. pneumoniae and resistant S. pneumoniae in children aged 12-18 months. 
VT, serotypes included in the vaccine (adapted from Austrian [32]). 
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Figure 5 The effect of a tetravalent (6B, 14, 19F and 23F) pneumococcal vaccine (either conjugated to tetanus toxoid (Pnc- 
T), or conjugated to hphtheria toxoid (Pnc-D)) on carriage of S. pneumoniae of the serotypes included in (6B, 14, 19F, 23F) 
or related to (6A) the vaccines, compared with placebo eflkct. VT, serotypes included in the vaccine. 
included in the vaccine were commonly found in 
children aged 21 months who had not received any 
pneumococcal vaccine previously (the carriage rate was 
83-90%). In contrast, those who had received the 
pentavalent conjugate vaccine at 2, 3 and 4 months of 
age carried the vaccine-related serotypes significantly 
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less frequently (50%; P value versus controls <0.005). 
(2) Contrary to the effect observed with the vaccine 
serotypes, the other pneumococcal serotypes were 
carried significantly more often by the vaccine recipients 
than by the controls (77% versus 43%; P<0.005). This 
preliminary observation on the promotion of carriage 
of S. pneurnoniae serotype not included in the vaccine 
by conjugate vaccine was provocative and raised several 
questions and concerns. 
Shortly after the observation from the Gambia, 
reduction of the serotypes included in the conjugate 
vaccine and replacement by other serotypes after 
immunization were confirmed by South African 
researchers, who immunized infants at  ages 6, 10 and 
14 weeks with a nine-valent (serotypes 1, 4, 5, 6B, 9V, 
14, 18C, 19F and 23F) pneumococcal vaccine con- 
jugated to c R k l 1 9 7  [43]. 
Our group undertook an extensive study to 
determine if carriage in toddlers attending day-care 
centers (which, as detailed above, are probably the main 
location associated with amplification and spread of 
resistant S. pneumoniae in the community) is affected by 
immunization. In a double-blind prospective randoni- 
ized study involving 264 toddlers during their second 
and third years of life, we immunized 132 toddlers with 
a nine-valent (containing serotypes 1, 4, 5, 6B, 9V, 14, 
18C, 19F, 23F) pneumococcal vaccine conjugated to 
c w 1 9 7  [44]. A nasopharyngeal culture was obtained 
before and once monthly after immunization for 1 year, 
and bi-monthly during the second year. Although the 
study will be completed only during the first quarter of 
1999, an interim analysis was done after 18 months of 
follow-up by a statistician not belonging to the study 
group [44]. At this time, 3646 cultures were obtained, 
with 2364 (68%) cultures being positive for S. pneu- 
rnoniae. Of  the 2364 pneumococcal isolates, 53%, 38% 
and 9% were resistant to at least one antibiotic, non- 
susceptible to penicillin and resistant to 1 3  drugs, 
respectively. The interim analysis showed the following 
points: (1) the carriage of pneumococci included in the 
vaccine was significantly reduced in vaccinees com- 
pared with controls; (2 )  the carriage of antibiotic- 
resistant pneumococci was significantly reduced in 
vaccinees compared with controls; (3) the total carriage 
of S.  pneumoniae was significantly reduced compared 
with controls; and (4) the carriage of pneumococcal 
serotypes not included in the vaccine was significantly 
increased compared with controls (Figure 6). 
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Figure 6 Effect of a nine-valent conjugate vaccine on the nasopharyngeal carriage of S. pneumoniae of the serotypes 
included in the vaccine (A), of antibiotic-resistant S. pneumoniae (B), of total S. pneumoniae (C), and of S. pneumoniae of other 
serotypes not included in the vaccine (D), in 132 children, compared with 132 receiving control vaccine. Children were 
12-35 months of age. At each determination, 66-132 children were examined. 
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The effect was observed mainly in those starting 
the study during their second year of life, and was 
almost not significant for those starting the study 
during the third year of life (not shown in the figure). 
What is the significance of the effect of conjugate 
vaccines on pneumococcal carriage observed so far? 
It is certain that some news is good: (1) the reduction 
of carriage of S. pneumoniae and resistant S. pneumoniae 
of the vaccine types suggests a potential for a strong 
herd immunity effect, permitting reduction of spread 
of the serotypes most commonly associated with disease 
and antibiotic resistance in the community; (2) the 
strong mucosal effect of the vaccine expressed by the 
reduction of nasopharyngeal carriage suggests that 
children may also be protected from otitis media, and 
thus permits us to be optimistic and to hope that the 
high efficacy against invasive pneumococcal infections 
shown recently with one conjugate vaccine [45] may 
not be confined to invasive infections, but may also 
show, in the future, efficacy against the much more 
common mucosal infections; and (3)  the effect of the 
vaccines on carriage may allow us in future to use 
reduction of carriage as an important surrogate of 
efficacy, if no placebo-controlled efficacy studies are 
allowed after introduction of pneumococcal conjugate 
vaccines to the immunization programs. 
However, some questions have been raised which 
should be answered before the optimism becomes 
reality. (1) Does the increase in the carriage of the 
serotypes not included in the vaccine represent a future 
threat? In other words, will it be associated with 
increased pneumococcal disease with these serotypes? 
(2) Will resistance spread to the serotypes not included 
in the vaccine that will now be carried more often? 
Certainly, these questions are important and cannot 
be answered in the immediate future. However, it is 
biologically plausible to assume that the replacement of 
carriage will not be associated with a replacement in 
disease, at least not to the same extent. The serotypes 
included in the vaccines, and especially the ones most 
resistant to antibiotics, are also most often less immuno- 
genic in children and can therefore be carried for long 
periods. This phenomenon allows them to be exposed 
to antibiotics for a longer period of time and thus to 
become more resistant. It can be speculated that the 
serotypes not included in the vaccine, which are also 
more immunogenic and therefore are carried for a 
shorter period of time, will have consequently less 
chance to become antibiotic resistant. However, anti- 
biotic resistance does also exist among some serotypes 
not included in the vaccine, especially in serotypes such 
as 6A and 19A, which are also quite important in 
disease, especially in otitis media. Although we do 
expect cross-protection between 6B and 6A, such 
cross-protection may not occur with 19F and 19A. 
Thus, some doubts still remain in regard to the 
beneficial effect of the conjugate vaccines on the 
pneumococcal nasopharyngeal flora, and it is possible 
that in the future some additional serotypes that are 
antibiotic resistant and cause disease will be added to 
the currently developed conjugate vaccine. 
In conclusion, carriage of antibiotic-resistant S. 
pneumoniae is frequent and is increasing worldwide, 
especially among infants and toddlers in crowded 
conditions. The use of vaccines may be one of the most 
efficient ways to fight this phenomenon, but other 
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